Yantai Dongcheng Biochemicals Co.,Ltd.(002675),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

002675 Yantai Dongcheng Biochemicals Co.,Ltd.

Trading 12-23 14:17:48

13.35

+0.07

+0.53%

High13.43	Low13.25	Vol5.98M
Open13.29	D1 Closing13.28	Amplitude1.36%
Mkt Cap11.01B	Tradable Cap9.92B	Total Shares825.00M
T/O79.85M	T/O Rate0.80%	Tradable Shares743.00M
P/B2.5	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"002675","market":"SZ","secType":"STK","nameCN":"Yantai Dongcheng Biochemicals Co.,Ltd.","latestPrice":13.35,"timestamp":1766470668000,"preClose":13.28,"halted":0,"volume":5979100,"delay":0,"changeRate":0.0053,"floatShares":743000000,"shares":825000000,"eps":0.2014,"marketStatus":"Trading","change":0.07,"latestTime":"12-23 14:17:48","open":13.29,"high":13.43,"low":13.25,"amount":79854600,"amplitude":0.0136,"askPrice":13.35,"askSize":32,"bidPrice":13.34,"bidSize":71,"shortable":0,"etf":0,"ttmEps":0.2014,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766473200000},"marketStatusCode":2,"adr":0,"adjPreClose":13.28,"symbolType":"stock","openAndCloseTimeList":[[1766453400000,1766460600000],[1766466000000,1766473200000]],"highLimit":14.61,"lowLimit":11.95,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":824595705,"isCdr":false,"pbRate":2.5,"roa":"--","peRate":66.285998,"roe":"3.37%","epsLYR":0.2229,"committee":0.658031,"marketValue":11008000000,"turnoverRate":0.008,"status":0,"floatMarketCap":9924000000},"requestUrl":"/m/hq/s/002675/tweets","defaultTab":"tweets","newsList":[{"id":"2590731377","title":"Dongcheng Pharmaceutical Subsidiary Gets Nod to Add New Specification for Dalteparin Sodium Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2590731377","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590731377?lang=en_us&edition=fundamental","pubTime":"2025-12-10 12:22","pubTimestamp":1765340532,"startTime":"0","endTime":"0","summary":"Yantai Dongcheng Pharmaceutical  subsidiary, Yantai Dongcheng Northern Pharmaceutical, received approval from China's National Medical Products Administration to add a new specification for dalteparin sodium injection, according to a Shenzhen bourse filing on Wednesday.The new specification to be marketed is 0.2 ml: 5000 AXa IU. The drug currently has a specification of 0.3 ml: 7500 AXa IU.The drug is used to treat acute deep vein thrombosis and unstable coronary artery disease, as well as prevent postoperative thrombosis and clotting during hemodialysis and hemofiltration.The pharmaceutical company's shares fell less than 2% during the midday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2589368483","title":"Dongcheng Pharmaceutical Subsidiary's Tiludronate Injection Placed in China's Medical Insurance List","url":"https://stock-news.laohu8.com/highlight/detail?id=2589368483","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589368483?lang=en_us&edition=fundamental","pubTime":"2025-12-08 17:23","pubTimestamp":1765185813,"startTime":"0","endTime":"0","summary":"Yantai Dongcheng Pharmaceutical  said the tiludronate injection of subsidiary Nanjing Jiangyuan Andico Positron Research and Development was included in China's Medical Insurance Catalogue, according to a Shenzhen bourse filing on Monday.The drug is used for diagnostic purposes for adults with coronary artery disease.The catalog will be implemented on Jan. 1, 2026.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2589728335","title":"Dongcheng Pharmaceutical's Unit Gets Nod for Clinical Trial of 177Lu-LNC1009 injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2589728335","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589728335?lang=en_us&edition=fundamental","pubTime":"2025-12-08 17:19","pubTimestamp":1765185547,"startTime":"0","endTime":"0","summary":"Yantai Dongcheng Pharmaceutical's  unit, Yantai Lannacheng Biotechnology, obtained approval from China's National Medical Products Administration for the clinical trial of 177Lu-LNC1009 Injection, according to a Shenzhen bourse disclosure on Monday.The drug is used to treat patients with advanced malignant solid tumors expressing fibroblast activation protein and integrin αvβ3.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2588888897","title":"Dongcheng Pharmaceutical's Unit Gets Radioactive Drug Manufacturing License","url":"https://stock-news.laohu8.com/highlight/detail?id=2588888897","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588888897?lang=en_us&edition=fundamental","pubTime":"2025-12-04 18:00","pubTimestamp":1764842428,"startTime":"0","endTime":"0","summary":"Yantai Dongcheng Pharmaceutical's  unit, Yantai Lannacheng Biotechnology, received a radioactive drug manufacturing license from the Shandong Provincial Medical Products Administration, according to a Shenzhen bourse filing on Thursday.The certificate, which is valid until Nov. 25, 2030, allows Lannacheng to produce in vivo radioactive drugs.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["002675","BK0239"],"gpt_icon":0},{"id":"1131116277","title":"Yantai Dongcheng Biochemicals' Subsidiary Lannacheng Biotechnology Obtains Radioactive Drug Production License","url":"https://stock-news.laohu8.com/highlight/detail?id=1131116277","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131116277?lang=en_us&edition=fundamental","pubTime":"2025-12-03 17:26","pubTimestamp":1764753973,"startTime":"0","endTime":"0","summary":"Yantai Dongcheng Biochemicals Co.,Ltd. (002675.SZ) announced that its subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., has received the \"Radioactive Drug Production License\" issued by the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002675","91284","BK0239"],"gpt_icon":0},{"id":"1126384229","title":"Yantai Dongcheng Biochemicals (002675.SZ) Completes Phase III Clinical Trial for Fluorine [18F]Sirateptide Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1126384229","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126384229?lang=en_us&edition=fundamental","pubTime":"2025-11-28 17:31","pubTimestamp":1764322312,"startTime":"0","endTime":"0","summary":"Yantai Dongcheng Biochemicals Co., Ltd. (002675.SZ) announced that its subsidiary, Yantai Lannacheng Biotechnology Co., Ltd. (\"Lannacheng\"), has completed Phase III clinical trials for Fluorine...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002675","BK0239","BK4134","III"],"gpt_icon":0},{"id":"1186666516","title":"Yantai Dongcheng Biochemicals: No Overdue External Guarantees by Company or Subsidiaries","url":"https://stock-news.laohu8.com/highlight/detail?id=1186666516","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186666516?lang=en_us&edition=fundamental","pubTime":"2025-11-13 22:31","pubTimestamp":1763044267,"startTime":"0","endTime":"0","summary":"On the evening of November 13, Yantai Dongcheng Biochemicals Co., Ltd. (002675) announced that as of the date of the announcement, the company has not provided guarantees for any entities or...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002675","BK0239"],"gpt_icon":0},{"id":"1165794445","title":"Yantai Dongcheng Biochemicals Co.,Ltd. (002675.SZ) Subsidiary Lannacheng Submits H-share IPO Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1165794445","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165794445?lang=en_us&edition=fundamental","pubTime":"2025-09-30 12:03","pubTimestamp":1759205031,"startTime":"0","endTime":"0","summary":"Yantai Dongcheng Biochemicals Co.,Ltd. (002675.SZ) announced that its subsidiary Yantai Lannacheng Biotechnology Co., Ltd. (referred to as \"Lannacheng\") has submitted application materials to the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2571584394","title":"BRIEF-Yantai Dongcheng's Unit Submits Listing Application To Hong Kong Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2571584394","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571584394?lang=en_us&edition=fundamental","pubTime":"2025-09-30 11:56","pubTimestamp":1759204574,"startTime":"0","endTime":"0","summary":"BRIEF-Yantai Dongcheng's Unit Submits Listing Application To Hong Kong Stock ExchangeSept 30  - Yantai Dongcheng Biochemicals Co Ltd 002675.SZ:SAYS UNIT HAS SUBMITTED LISTING APPLICATION TO HONG KONG STOCK EXCHANGESource textFurther company coverage: 002675.SZ  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nL3N3VH09I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2569720916","title":"Yantai Dongcheng Pharmaceutical Gets Regulatory Nod for Prostate Cancer Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2569720916","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569720916?lang=en_us&edition=fundamental","pubTime":"2025-09-24 14:23","pubTimestamp":1758695030,"startTime":"0","endTime":"0","summary":"Yantai Dongcheng Pharmaceutical (SHE:002675) subsidiary Lannacheng obtained the approval of China's drug administrator to start clinical trials for its 225Ac-LNC1011 injection.The drug is a radiopharm","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"1116037660","title":"Yantai Dongcheng Biochemicals (002675.SZ): 225Ac-LNC1011 Injection Receives Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1116037660","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116037660?lang=en_us&edition=fundamental","pubTime":"2025-09-23 17:22","pubTimestamp":1758619353,"startTime":"0","endTime":"0","summary":"Yantai Dongcheng Biochemicals Co.,Ltd. (002675.SZ) announced that its controlling subsidiary, Yantai Lanacheng Biotechnology Co., Ltd. (referred to as \"Lanacheng\"), has received a clinical trial...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2562809053","title":"Yantai Dongcheng Biochemicals  Says Co Plans to Spin off Unit for Hong Kong Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2562809053","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562809053?lang=en_us&edition=fundamental","pubTime":"2025-08-28 21:47","pubTimestamp":1756388861,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nL4N3UK19N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2562053340","title":"BRIEF-Yantai Dongcheng Biochemicals To Spin Off Unit For Hong Kong Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2562053340","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562053340?lang=en_us&edition=fundamental","pubTime":"2025-08-28 21:47","pubTimestamp":1756388861,"startTime":"0","endTime":"0","summary":"BRIEF-Yantai Dongcheng Biochemicals To Spin Off Unit For Hong Kong ListingAug 28  - Yantai Dongcheng Biochemicals Co Ltd 002675.SZ:SAYS CO PLANS TO SPIN OFF UNIT FOR HONG KONG LISTINGSource textFurther company coverage: 002675.SZ  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nL4N3UK19N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2561478273","title":"Yantai Dongcheng Pharmaceutical Group Gets US FDA Approval for Prostate Cancer Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2561478273","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561478273?lang=en_us&edition=fundamental","pubTime":"2025-08-22 18:13","pubTimestamp":1755857622,"startTime":"0","endTime":"0","summary":"Yantai Dongcheng Pharmaceutical Group  subsidiary Blue Nucleic Pharmaceutical obtained the approval of the US Food and Drug Administration to start phase one clinical trials for its 225Ac-LNC1011 injection.The clinical trials will test the drug for treating prostate cancer, according to a Friday filing with the Shenzhen bourse.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2561644249","title":"BRIEF-Yantai's Unit Gets US FDA's greenlight On Clinical Trial Of Ac-LNC1011 For Prostate Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2561644249","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561644249?lang=en_us&edition=fundamental","pubTime":"2025-08-22 12:00","pubTimestamp":1755835218,"startTime":"0","endTime":"0","summary":"BRIEF-Yantai's Unit Gets US FDA's greenlight On Clinical Trial Of Ac-LNC1011 For Prostate Cancer TreatmentAug 22  - Yantai Dongcheng Biochemicals Co Ltd 002675.SZ:SAYS UNIT RECEIVES \"STUDY MAY PROCEED LETTER\" FROM U.S. FDA ON CLINICAL TRIAL OF AC-LNC1011 FOR PROSTATE CANCER TREATMENTSource textFurther company coverage: 002675.SZ  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nL4N3UE09J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2561442936","title":"Yantai Dongcheng  Says Unit Receives \"Study May Proceed Letter\" From U.S. FDA on Clinical Trial of Ac-Lnc1011 for Prostate Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2561442936","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561442936?lang=en_us&edition=fundamental","pubTime":"2025-08-22 12:00","pubTimestamp":1755835218,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nL4N3UE09J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"1102185198","title":"Yantai Dongcheng Biochemicals Co.,Ltd. (002675.SZ) Subsidiary Receives Clinical Trial Approval Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=1102185198","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102185198?lang=en_us&edition=fundamental","pubTime":"2025-08-22 11:56","pubTimestamp":1755834991,"startTime":"0","endTime":"0","summary":"Yantai Dongcheng Biochemicals Co.,Ltd. (002675.SZ) announced that on August 22, 2025, its subsidiary LNC PHARMA PTE. LTD. received a Study May Proceed Letter (SMP) from the U.S. Food and Drug...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002675","BK0239"],"gpt_icon":0},{"id":"2555058055","title":"Dongcheng Pharmaceutical Subsidiary Secures Radioactive Drug Manufacturing License","url":"https://stock-news.laohu8.com/highlight/detail?id=2555058055","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555058055?lang=en_us&edition=fundamental","pubTime":"2025-07-29 19:09","pubTimestamp":1753787356,"startTime":"0","endTime":"0","summary":"Yantai Dongcheng Pharmaceutical  subsidiary Xinkesida obtained a radioactive drug manufacturing license from the medical products administrator of China's Shandong province.The license permits the production of in vivo radioactive lyophilized powder injections at its Yantai facility, with validity until July 14, 2030, according to a Tuesday filing with the Shenzhen bourse.Shares of the pharmaceutical company closed 2% higher Tuesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"2551656148","title":"Dongcheng Pharmaceutical Starts Operations at Jiangxi Nuclear Medicine Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2551656148","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551656148?lang=en_us&edition=fundamental","pubTime":"2025-07-16 15:28","pubTimestamp":1752650928,"startTime":"0","endTime":"0","summary":"Yantai Dongcheng Pharmaceutical Group (SHE:002675) said its Jiangxi Yichun nuclear medicine production center received good manufacturing practices certification and began operations.The facility, ope","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","002675"],"gpt_icon":0},{"id":"1107591808","title":"Yantai Dongcheng Biochemicals (002675.SZ): Jiangxi Yichun Nuclear Medicine Production Center Commences Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=1107591808","media":"Stock Track","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107591808?lang=en_us&edition=fundamental","pubTime":"2025-07-15 18:12","pubTimestamp":1752574330,"startTime":"0","endTime":"0","summary":"Yantai Dongcheng Biochemicals Co., Ltd. (002675.SZ) announced that its wholly-owned subsidiary Jiangxi Andike Pharmaceutical Co., Ltd. (\"Jiangxi Andike\") has received the Drug GMP Compliance...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BK0239","002675"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2012-05-25","address":"山东省烟台市福山区经济技术开发区长白山路7号","stockEarnings":[{"period":"1week","weight":-0.0257},{"period":"1month","weight":-0.1021},{"period":"3month","weight":-0.1194},{"period":"6month","weight":-0.086},{"period":"1year","weight":0.0595},{"period":"ytd","weight":0.0891}],"companyName":"烟台东诚药业集团股份有限公司","boardCode":"AI0027","perCapita":"30191股","boardName":"医药制造业","registeredCapital":"82459万元","compareEarnings":[{"period":"1week","weight":0.0128},{"period":"1month","weight":0.0215},{"period":"3month","weight":0.025},{"period":"6month","weight":0.1335},{"period":"1year","weight":0.1631},{"period":"ytd","weight":0.1687}],"survey":"　　烟台东诚药业集团股份有限公司的主营业务是放射性核素药物、抗凝血肝素类原料药及其下游制剂的生产销售。公司的主要产品是氟[18F]脱氧葡糖注射液（18F-FDG）、云克注射液（锝[99Tc]亚甲基二膦酸盐注射液）、锝[99mTc]标记药物、尿素[14C]胶囊、碘[131I]化钠口服液、锝[99mTc]替曲膦注射液、氟[18F]化钠注射液硫酸软骨素、那屈肝素钙注射液、注射用氢化可的松琥珀酸钠、达肝素钠注射液、依诺肝素钠注射液、注射用绒促性素、注射用尿促性素、咽炎清滴丸、消风止痒颗粒、盐酸氨溴索分散片、二甲双胍格列本脲片（Ⅰ）、银黄滴丸、益肝灵滴丸。公司是国内最大的生化原料药供应商之一，硫酸软骨素依靠产业链体系建立优势，是全球最大药品级和膳食补充剂级硫酸软骨素供应商。","serverTime":1766470670620,"listedPrice":26,"stockholders":"24622人(较上一季度增加4.51%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Yantai Dongcheng Biochemicals Co.,Ltd.(002675),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Yantai Dongcheng Biochemicals Co.,Ltd.(002675) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Yantai Dongcheng Biochemicals Co.,Ltd.,002675,Yantai Dongcheng Biochemicals Co.,Ltd.股票,Yantai Dongcheng Biochemicals Co.,Ltd.股票老虎,Yantai Dongcheng Biochemicals Co.,Ltd.股票老虎国际,Yantai Dongcheng Biochemicals Co.,Ltd.行情,Yantai Dongcheng Biochemicals Co.,Ltd.股票行情,Yantai Dongcheng Biochemicals Co.,Ltd.股价,Yantai Dongcheng Biochemicals Co.,Ltd.股市,Yantai Dongcheng Biochemicals Co.,Ltd.股票价格,Yantai Dongcheng Biochemicals Co.,Ltd.股票交易,Yantai Dongcheng Biochemicals Co.,Ltd.股票购买,Yantai Dongcheng Biochemicals Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Yantai Dongcheng Biochemicals Co.,Ltd.(002675),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Yantai Dongcheng Biochemicals Co.,Ltd.(002675) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction